010600 — WellBiotec Co Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeMicro Cap

Annual income statement for WellBiotec Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS/A	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	60,431	108,377	158,116	59,746	83,301
Cost of Revenue
Gross Profit	6,408	9,288	22,220	7,542	9,703
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	103,805	120,520	161,368	70,637	94,243
Operating Profit	-43,373	-12,143	-3,252	-10,890	-10,941
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-51,129	-34,555	-19,633	-60,113	-18,761
Provision for Income Taxes
Net Income After Taxes	-50,908	-34,879	-21,024	-60,544	-19,218
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-67,431	-33,279	-20,881	-64,910	-21,220
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-67,431	-33,279	-20,881	-64,910	-21,220
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-707	-538	-269	-764	-176
Dividends per Share